Health and Human Services Secretary nominee Robert F. Kennedy Jr.’s concerns about the pharmaceutical industry apparently extend far beyond his well-known anti-vaccine sentiments.
Beyond Vaccines: Kennedy’s Anti-Pharma Side On Display At Senate Hearings
Health and Human Services Department Secretary nominee Robert F. Kennedy Jr. falsely said prescription drugs are the third leading cause of death and made other comments on corporate capture, mifepristone, anti-depressants, and ADHD treatments, suggesting someone who often sows doubt and misleads on the risk-benefit balance of pharmaceuticals.
More from Leadership
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
More from Drug Pricing
• By
US President Trump’s threat of a “25% or higher” import tariff on pharmaceuticals sends ripples through an already uncertain environment. With about half of generics sourced from India, captains of industry read between the lines
• By
Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.
• By
Sun Pharma sees opportunities for Antibe’s otenaproxesul in the US and emerging markets and aims to get the clinical hold on the novel NSAID lifted. The firm is also focusing on its specialty business in Japan, amid pricing challenges for long-listed products.